These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 27282497)

  • 1. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
    Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
    Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
    Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H
    Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
    Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
    Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PIK3CA gene mutations in Chinese women with HR
    Wu SF; Wang XF; Liu YY; Xia C; Liang ZY; Zeng X
    Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1246-1250. PubMed ID: 36480834
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
    Bisht S; Ahmad F; Sawaimoon S; Bhatia S; Das BR
    Med Oncol; 2014 Sep; 31(9):124. PubMed ID: 25073438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
    Zhang Y; Liu M; Yang H; Wang J; Liu H; Li X; Li J; Xu J; Li X
    Neoplasma; 2014; 61(4):461-7. PubMed ID: 25027743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
    Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
    PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
    Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
    Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
    Filipenko ML; Os'kina NA; Oskorbin IA; Mishukova OV; Ovchinnikova LK; Gershtein ES; Kushlinskii NE
    Bull Exp Biol Med; 2017 Jun; 163(2):250-254. PubMed ID: 28726194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients.
    Elwy F; Helwa R; El Leithy AA; Shehab El din Z; Assem MM; Hassan NH
    Asian Pac J Cancer Prev; 2017 Jan; 18(1):57-64. PubMed ID: 28240010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
    Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
    Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
    Liedtke C; Cardone L; Tordai A; Yan K; Gomez HL; Figureoa LJ; Hubbard RE; Valero V; Souchon EA; Symmans WF; Hortobagyi GN; Bardelli A; Pusztai L
    Breast Cancer Res; 2008; 10(2):R27. PubMed ID: 18371219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
    Jia M; Liao N; Chen B; Zhang G; Wang Y; Li X; Cao L; Mok H; Ren C; Li K; Li C; Wen L; Lin J; Wei G; Balch CM
    Breast Cancer; 2021 May; 28(3):644-652. PubMed ID: 33386585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutation associates with improved outcome in breast cancer.
    Kalinsky K; Jacks LM; Heguy A; Patil S; Drobnjak M; Bhanot UK; Hedvat CV; Traina TA; Solit D; Gerald W; Moynahan ME
    Clin Cancer Res; 2009 Aug; 15(16):5049-59. PubMed ID: 19671852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA mutations in breast cancer: A Tunisian series.
    Ben Rekaya M; Sassi F; Saied E; Bel Haj Kacem L; Mansouri N; Zarrouk S; Azouz S; Rammeh S
    PLoS One; 2023; 18(5):e0285413. PubMed ID: 37195967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
    World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
    Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M; González-Farré B; Sanfeliu E; Schettini F; Conte B; Brasó-Maristany F; Rodríguez A; Martínez D; Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A
    Breast Cancer Res; 2020 May; 22(1):45. PubMed ID: 32404150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.